MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) managing director Roby Zomer hailed the ‘big leap forward’ made by researchers carrying out a preclinical assessment of one of its lead asset's potential efficacy in inflammation.
Preliminary results from the study revealed that CimetrA has a wide-ranging application as an anti-inflammatory treatment through the modulation of cytokines.
These small proteins when over-produced create what is called a cytokine storm of the type found in people suffering severe Covid. Indeed, CimetrA has previously been shown to help modulate cytokines in those with moderate symptoms of the illness.
However, the latest trial, undertaken by Israeli contract research organisation Science in Action, has homed in on exactly how CimetrA works and, specifically, its ability to effectively block IL-32mRNA expression.
IL-32mRNA is a pro-inflammatory cytokine related to rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis and chronic obstructive pulmonary disease.
“We have long had confidence in CimetrA, and this latest study on its mechanism of action highlights even more potential applications for the product,” said MD Zomer.
“This is a big leap forward, with more conditions potentially being able to be treated treatable with the drug.
"Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirm the findings of previous studies.”
The company said it is currently making plans for the next phase of CimetrA’s “clinical journey”.